Search results
Results from the WOW.Com Content Network
The approval was updated in September 2021, to include people aged twelve and older. [14] The Moderna Spikevax COVID-19 vaccine was authorized in Canada in September 2021, for people aged 12 and older. [22] [4] [182] The Moderna Spikevax COVID-19 vaccine was authorized in the US in January 2022, for people aged 18 and older. [1] [38] [41]
Moderna is also expecting to get approval to expand the label to high-risk people under the age of 60. It sees the expansion of the product to younger adults as having a $10 billion total ...
The Moderna COVID-19 vaccine, also known as Spikevax, [318] is an mRNA vaccine [319] produced by the American company Moderna, the U.S. National Institute of Allergy and Infectious Diseases, the U.S. Biomedical Advanced Research and Development Authority, and the Coalition for Epidemic Preparedness Innovations.
Yahoo Finance’s Brian Sozzi and Alexis Christoforous break down the market action for Moderna, after the company announced it received FDA clearance for its coronavirus vaccine for phase 2 trial.
The company's stock was trading slightly up on the news early Monday before falling after market open. Moderna is up almost 20% in the last month after the company received approval from the FDA ...
In September 2023, the FDA approved an updated monovalent (single) component Omicron variant XBB.1.5 version of the vaccine (Comirnaty 2023–2024 formula) as a single dose for individuals aged twelve years of age and older; [30] and authorized the Pfizer-BioNTech COVID-19 Vaccine 2023–2024 formula under emergency use for individuals aged 6 ...
Moderna held its annual R&D day this week. Moderna's (NASDAQ: MRNA) struggles may last a little longer than expected. The biotech company had seen both sales and its stock price plummet as demand ...
In March 2020, the Food and Drug Administration approved clinical trials for the Moderna COVID‑19 vaccine candidate, and in December, the vaccine, mRNA-1273, was issued an emergency use authorization in the United States. [35] [36] In 2022, it gained FDA approval both for the monovalent vaccine, Spikevax, and a bivalent booster. [37]